Rheumatoid Arthritis Drugs Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026
Report Highlights
Global Rheumatoid Arthritis Drugs Market: Overview
This report on the rheumatoid arthritis drugs market analyzes the current and future scenario of the global market. Rise in geriatric population, high prevalence of rheumatoid arthritis, and increase in patient preference for biological origin drugs are major drivers of the global rheumatoid arthritis drugs market.
The rheumatoid arthritis drugs market report comprises an executive summary, which includes a market synopsis that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug type, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, in terms of geography, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global rheumatoid arthritis drugs market.
Global Rheumatoid Arthritis Drugs Market: Key Segments
The global rheumatoid arthritis drugs market can be segmented based on rheumatoid arthritis drug type, distribution channel, and geography. Furthermore, in terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis market during the forecast period, owing to wide usage of these drugs in moderate to severe disease condition. Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Rheumatoid Arthritis Drugs Market: Regional Outlook
Based on geography, the global rheumatoid arthritis drugs market has been categorized into five major regions, and the key countries in the respective region are: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2018 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global rheumatoid arthritis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global rheumatoid arthritis drugs market include Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.
The global rheumatoid arthritis drugs market has been segmented as given below:
Global Rheumatoid Arthritis Drugs Market Revenue, by Drug Type, 2016–2026
Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
Corticosteroids
Disease Modifying Anti-rheumatic Drugs (DMARDs)
Biologic Response Modifiers (Biologics)
Global Rheumatoid Arthritis Drugs Market Revenue, by Distribution Channel, 2016–2026
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Rheumatoid Arthritis Drugs Market Revenue, by Geography, 2016–2026
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC countries
South Africa
Rest of Middle East & Africa
- Table 1 : Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 2 : Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 3 : Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2026
- Table 4 : North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country, 2018–2026
- Table 5 : North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 6 : North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 7 : Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
- Table 8 : Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 9 : Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 10 : Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
- Table 11 : Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 12 : Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 13 : Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
- Table 14 : Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 15 : Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Table 16 : Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
- Table 17 : Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
- Table 18 : Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
- Figure 1 : Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, 2016–2026
- Figure 2 : Global Rheumatoid Arthritis Drugs Market Value Share, by Drug Type (2017)
- Figure 3 : Global Rheumatoid Arthritis Drugs Market Value Share, by Distribution Channel (2017)
- Figure 4 : Global Rheumatoid Arthritis Drugs Market Value Share, by Region (2017)
- Figure 5 : Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 6 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2016–2026
- Figure 7 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2016–2026
- Figure 8 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2016–2026
- Figure 9 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2016–2026
- Figure 10 : Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 11 : Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 12 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016–2026
- Figure 13 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016–2026
- Figure 14 : Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2026
- Figure 15 : Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 16 : Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region, 2017 and 2026
- Figure 17 : Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region, 2018?2026
- Figure 18 : North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
- Figure 19 : North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 20 : North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 21 : North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 22 : North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 23 : North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country, 2018–2026
- Figure 24 : Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
- Figure 25 : Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 26 : Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 27 : Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 28 : Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 29 : Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
- Figure 30 : Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
- Figure 31 : Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 32 : Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 33 : Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 34 : Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 35 : Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
- Figure 36 : Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
- Figure 37 : Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 38 : Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 39 : Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 40 : Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 41 : Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
- Figure 42 : Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
- Figure 43 : Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
- Figure 44 : Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
- Figure 45 : Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
- Figure 46 : Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
- Figure 47 : Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018
- Figure 48 : AbbVie, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 49 : AbbVie, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
- Figure 50 : AbbVie, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
- Figure 51 : AbbVie, Inc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 52 : Janssen Biotech, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
- Figure 53 : Janssen Biotech, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
- Figure 54 : Janssen Biotech, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
- Figure 55 : Janssen Biotech, Inc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 56 : Amgen, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 57 : Amgen, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
- Figure 58 : Amgen, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
- Figure 59 : Amgen, Inc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 60 : Pfizer, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 61 : Pfizer, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
- Figure 62 : Pfizer, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
- Figure 63 : Pfizer, Inc. Breakdown of Net Sales, by Business Segment, 2017
- Figure 64 : Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 65 : Novartis AG R&D Expenses (US$ Mn) – Company Level, 2015–2017
- Figure 66 : Novartis AG Breakdown of Net Sales (Surgical Products), by Region 2017
- Figure 67 : Novartis AG Breakdown of Net Sales, by Business Segment, 2017
- Figure 68 : Sanofi S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
- Figure 69 : Sanofi S.A. R&D Intensity (%) 2015–2016
- Figure 70 : Sanofi S.A. Breakdown of Net Sales, by Region, 2017
- Figure 71 : Sanofi S.A. Breakdown of Net Sales, by Segment, 2017
- Figure 72 : F. Hoffmann-La Roche Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
- Figure 73 : F. Hoffmann-La Roche Ltd. R&D Intensity (US$ Mn), 2015–2017
- Figure 74 : F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region, 2017
- Figure 75 : F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Segment, 2017
- Figure 76 : Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 77 : Merck & Co., Inc. R&D Intensity (US$ Mn), 2015–2017
- Figure 78 : Merck & Co., Inc. Breakdown of Net Sales, by Region, 2016
- Figure 79 : Merck & Co., Inc. Breakdown of Net Sales, by Segment, 2017
- Figure 80 : Bristol-Myers Squibb Company Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
- Figure 81 : Bristol-Myers Squibb Company R&D Intensity (US$ Mn), 2015–2017
- Figure 82 : Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2017
- Figure 83 : Eli Lilly and Company Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2017
- Figure 84 : Eli Lilly and Company R &D Intensity (US$ Mn), 2015–2017
- Figure 85 : Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2017
- Figure 86 : Eli Lilly and Company Breakdown of Net Sales, by Therapeutic Areas, 2017
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.